Ensuring top value of a product throughout the lifecycle process involves managing issues related to evaluating a potential product; Identifying the best people for a project, recognizing key value factors of a product, and managing the size, flow and duration of a project. This panel specifically addressed:
- How does your evaluation of a project differ in the big Pharma setting vs. a more entrepreneurial setting?
- What factors do you consider in determining whether their will be life after the patent on the active
- How have considerations changed in doing research (basic and developmental) in the last 10 years?
- What are some sources for evaluating the likelihood of success of a project?
Presenters included:
- Lisa Alexander, Corporate Patent Counsel, Novartis Institutes for Biomedical Research; Novartis Vaccines & Diagnostics
- Matt Bastardi, Vice President, Business Development & Licensing, Covidien
- James Burnes, Director, Health Care Investment Banking, Credit Suisse Securities LLC
- R. Brian McCaslin, Senior Counsel, Biotechnology & Pharmaceutical Practice, Foley
Related Insights
June 18, 2025
Energy Current
Texas Energizes Nuclear Energy Strategy with Passage of Three Key Bills
The Texas Legislature recently passed three key bills: House Bill 14 (H.B. 14); Senate Bill 1061 (S.B. 1061); and Senate Bill 1535 (S.B….
June 18, 2025
Energy Current
FERC Issues Guidance on Treatment of Criminal Regulatory Offenses
On June 16, 2025, the Federal Energy Regulatory Commission (FERC) issued a Notice of Guidance regarding the consistency of its existing…
June 18, 2025
Foley Viewpoints
Legal Reasoning Still a Struggle for LLMs
The authors in this paper created a benchmark including long-form, open-ended questions and multiple-choice questions to evaluate the…